Aurobindo Pharma reported INR25.68B in Cost of Sales for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cost Of Sales Change
Cipla CIPLA:IN INR 21.6B 1.36B
Dr.Reddys Laboratories DRRD:IN INR 18.47B 643M
Hindustan Unilever HUVR:IN INR 81.97B 5.33B
Sun Pharmaceuticals SUNP:IN INR 27.08B 1.92B
UPL UPLL:IN INR 57.81B 11.17B